NASDAQ: MLYSMineralys Therapeutics Inc Stock
$23.92+0.30 (+1.27%)
Updated Jun 15, 2026
MLYS Price
$23.92
Fair Value Price
$2.56
Market Cap
$1.97B
52 Week Low
$12.59
52 Week High
$47.65
P/E
-11.96x
P/B
3.09x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$151.78M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.02
Operating Cash Flow
-$136M
Beta
1
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
MLYS Overview
Mineralys Therapeutics, Inc. (MLYS) is a pioneering biopharmaceutical company currently advancing through clinical trials. Its primary focus lies in creating innovative treatments for high blood pressure and its related cardiovascular complications. The company's leading investigational drug is lorundrostat. This exclusive, orally administered compound functions as a highly targeted aldosterone synthase inhibitor, specifically being developed to address difficult-to-treat cases of uncontrolled or resistant hypertension. Established in 2019, Mineralys Therapeutics operates from its headquarters in Radnor, Pennsylvania.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine MLYS's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
MLYS
Ranked#276 of 462
Ranked#276 of 462
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $230.59 | A | |
| $53.00 | A | |
| $16.00 | A |
Be the first to know about important MLYS news, forecast changes, insider trades & much more!
MLYS News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how MLYS scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
MLYS ($23.92) is overvalued by 835.88% relative to our estimate of its Fair Value price of $2.56 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
MLYS ($23.92) is not significantly undervalued (835.88%) relative to our estimate of its Fair Value price of $2.56 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
MLYS is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more MLYS due diligence checks available for Premium users.
Valuation
MLYS fair value
Fair Value of MLYS stock based on Discounted Cash Flow (DCF)
Price
$23.92
Fair Value
$2.56
Overvalued by
835.88%
MLYS ($23.92) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
MLYS ($23.92) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
MLYS is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
MLYS price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-11.96x
Industry
16.41x
Market
14.3x
MLYS price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
3.09x
Industry
4.89x
MLYS is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
MLYS's financial health
Profit margin
Revenue
$0.0
Net Income
-$39.3M
Profit Margin
0%
MLYS's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$652.9M
Liabilities
$14.7M
Debt to equity
0.02
MLYS's short-term assets ($652.47M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
MLYS's short-term assets ($652.47M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
MLYS's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$39.5M
Investing
-$44.9M
Financing
$24.3M
MLYS's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
MLYS vs Biotech Stocks
Mineralys Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.